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Abstract 
 
Platinum based adjuvant chemotherapy is generally recommended for ovarian cancer to improve the survival rate. 
Intravenous route is commonly used, easily administered and less associated complications. However, intraperitoneal 
route is gaining its popularity as a single procedure or adjunctive to the intravenous route. Numerous questions on its 
eligibility and safety are still perplexed. A case review on a patient with non optimal debulking surgery of advanced 
ovarian cancer was studied. Intravenous platinum based chemotherapy combined with paclitaxel failed to bring her 
to clinical remission. Second line chemotherapy, gemcitabin rendered her to poor response with unresolved 
debilitating ascites needing recurrent drainage. Surprisingly, a trial of intraperitoneal chemotherapy with cisplatin 
revealed a great response with a complete clinical remission. 
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Introduction 
 
Advanced stage ovarian cancer theoretically has a poor 
5-year survival rate of approximately 30%–50% for 
stage III disease (1). Generally accepted management 
of ovarian malignancy includes staging laparotomy 
and primary optimal debulking followed by adjuvant 
intravenous chemotherapy (2). Neoadjuvant 
chemotherapy followed by interval debulking is 
reserved for the inoperable cases where subsequent 
surgery is aimed at complete clearance of the tumour 
mass in chemosensitive patients. 
 
Intravenous chemotherapy which consist of platinum 
based agents (carboplatin and cisplatin) and taxane are 
extensively studied in order to obtain optimal response 
and prolonged remission resulting to improve survival 
rate. Yet, in many areas, it still remains implausible to 
achieve the goals and the management strategies 
mainly depending on the individual assessment. 
Although intraperitoneal (IP) chemotherapy is 
considered as an acceptable option for ovarian cancer 
with small residual tumour following a debulking 
surgery, and has shown an improvement in median 
survival rate by approximately 16 months, (2,3) but it 
is not widely practiced. 
 
By biological rationale, ovarian cancer largely 
confined to the peritoneal cavity, which IP is an ideal 
treatment for residual disease. The efficacy of the IP 
chemotherapy has been widely tested in phase 1/11 
clinical trials with established result in its 
pharmacokinetic actions and safety profiles. Therefore, 
this approach is deemed a vital alternative to consider 
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in such patients after first or second line treatment. In a 
small volume disease less than 1 cm, 30-40% had 
responded to IP cisplatin (2,3). More recently, 
paclitaxel was found to have distinct pharmacological 
advantages when administered intraperitoneally 
(4,5,6). The disease-free survival was found to be 
significantly prolonged in the IP approach compared to 
the intravenous route with median recurrent interval of 
27.9 months and 22.2 months respectively (3). In 
addition, the IP arm had a longer overall survival of 
63.2 months compared to 52.2 months in intravenous 
route chemotherapy (3).  However, there are very 
limited evidences on a large volume disease (more 
than 1 cm in diameter) or palliative benefits.  In one 
published series dealing with disease management 
found that patients who had even a single lesion of at 
least 1 cm in diameter has a poor clinical response rate 
of less than 10% (2). 
 
Traditionally, IP chemotherapy is used in ovarian 
cancer mainly for the symptomatic relief of gross 
ascites. It has a better penetration to the tumour site 
with potential reduction of systemic absorption (4). 
The ideal technique, dosage, choice of agents and the 
duration of treatment are not very extensive reviewed 
in the randomized controlled trial and remained 
inconclusive. Largely its usage depends on the 
individual clinical experience.   
 
Case Report 
 
A 55-year-old, postmenopausal lady, para 3, first 
presented in July 2006 with acute abdomen with 
suspected twisted ovarian cyst and had an emergency 
staging laparotomy and right salpingo-oophorectomy 
with omentectomy following peritoneal washing. A 
complete debulking surgery was not able to achieve as it 
was difficult due to advanced tumour deposit with the 
left ovary adhered densely to the bowel and uterus. The 
histopathology examination confirmed serous 
cystadenocarcinoma of the ovary grade 3 with positive 
peritoneal washing and microscopic evidence of 
omental deposit.  
 
Following surgery, she was commenced on three cycles 
of chemotherapy, combination of carboplatin and   
paclitaxel before undergoing a complete debulking 
surgery. Computed tomography of abdomen and pelvis 
following chemotherapy revealed a residual disease 
involving the contralateral ovary with suspected bowel 
involvement but non-significant nodal or liver 
metastasis. An optimal debulking surgery with 
hysterectomy, left salpingo-oophorectomy and pelvic 
nodes dissection was then performed with postoperative 
chemotherapy (carboplatin and paclitaxel) was 
administered. Biochemically, showed poor response of 
the treatment with persistently elevated CA125 level 
and CT scan of pelvis and abdomen revealed gross 
ascites with large pelvic mass measuring 6.2 cm by 6.5 
cm by 5.4 cm appeared to be continuity with the ascites. 
A subcutaneous lesion measuring 2.1 cm by 1.2 cm 
seen at the right lower quadrant of the abdomen (Fig. 1). 
No pelvic adnaexal mass or enlarged paraaortic, 
inguinal or mesentrics nodes. No other abnormality of 
note. Following third cycles of carboplatin and 
paclitaxel, she was started on second line chemotherapy 
gemcitabin for two cycles as no clinical response. In 
fact, she required three episodes of peritoneal tapping to 
relief discomfort and respiratory embarrassment due to 
gross ascites. 
 
Following discussion with patient, an intraperitoneal 
chemotherapy with cisplatin 50 mg was administered 
following abdominal tapping of two litres of straw 
colour ascites. The patient tolerated well with no 
apparent adverse effects. Two weeks later, abdominal 
distension had decreased, CA125 level reduced and she 
was very happy to complete three cycles of IP cisplatin. 
Amazingly, after the third course, she was 
asymptomatic for any tumour recurrence, no ascites 
dropped in CA125 significantly and a repeat CT scan of 
abdomen and pelvis revealed a significant improvement 
(Fig. 2). 
 
Discussion 
 
Intraperitoneal (IP) chemotherapy is not an 
extraordinary invention in the new era of management 
of ovarian cancer.  It had been used extensively in the 
past not only in the small residual disease but also as 
palliative chemotherapy. However, to date, this 
modality is still remains an issue in term of its 
effectiveness, safety and selection of cases.  
 
The illustrated case was outstandingly proven the 
effectiveness of IP chemotherapy (cisplatin) in the 
management of advanced ovarian cancer even with 
suboptimal cytoreduction or residual disease of more 
than 1 cm. More interestingly, a failed systemic 
intravenous chemotherapy using platinum based agent 
and paclitaxel followed by second line gemcitabin 
after no clinical response did not preclude benefits of 
intraperitoneal route. More so, extensive peritoneal 
disease found in this patient did not allay adequate 
distribution of the IP chemotherapy which was 
suggested by previous authors (7,8,9,10,11).  
 
Although many studies addressed on the approach to 
reduce the risk associated with peritoneal cavity access 
including laparoscopic technique, and related issues on 
the type of catheters and when they should be inserted, 
yet this matter is still inconclusive (12). However, a  
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Figure 1: Axial contrast enhanced CT Abdomen shows 
multiple lobulated enhancing peritoneal masses anterior and 
lateral to the liver (white arrows). Presence of ascites also 
noted. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Follow up CT post-chemotherapy 4 months later, 
shows significant reduction in size of the peritoneal masses 
(white arrows) at the perihepatic area with minimal residual 
ascites. 
 
simple large venous canulae sized 14 G placed under 
ultrasound guidance that we practiced in this case 
produced an excellent effect without any 
complications.  
 
Previous large studies had demonstrated an optimal 
dose of 100 mg/m2 cisplatin every three weeks with 
excellent results (10,11,12). Further randomized 
controlled trial had attempted to evaluate the effect of 
50-100 mg/m2 carboplatin with area under 
concentration versus time curve (AUC) 12 to AUC 6 
and AUC 8 to AUC 4 respectively. Interestingly, all 
the findings demonstrated a comparable effect on 
progression-free disease and overall survivals (5).  
Even though the existing evident support various 
issues including therapeutic efficacy of IP, but it is still 
in conflict and difficult to justify that intraperitoneal 
cisplatin is superior than intravenous carboplatin 
(8,9,10,11). 
 
Patients with malignant ascites are suggested to 
undergo drainage followed by IP installation of the 
chemotherapy. This basically for symptomatic relief of 
the distended abdomen added to further installation 
and maintaining desired concentration of the 
chemotherapy. More so, in this case who required 
multiple decompressions of the distended abdomen 
due to respiratory embarrassment and abdominal pain.  
Administration of IP exacerbates the development of 
intraabdominal adhesion making subsequent 
abdominal surgery more risky (13). In balancing the 
risk-benefits, proper assessment and discussion on the 
targeted issues need to be addressed to the patient. 
 
There are reports suggesting the combination of 
intravenous chemotherapy (paclitaxel or docetaxel) 
followed by intraperitoneal route of platinum agents 
(cisplatin or carboplatin). The reason behind this is to 
delay the regional chemotherapy while the healing 
from cytoreductive surgery taking place. The result did 
not favor any specific approach as similar outcome 
had been observed. It is wise to consider the effective 
dose treatment and agents without creating any 
untoward effects to the patient. This patient had two 
courses of combination carboplatin and paclitaxel 
without any clinical response but amazingly, the 
disease had significantly improved following three 
cycles of IP cisplatin. 
 
Based on this case and supported by other previous 
studies, it is clearly shown that IP chemotherapy works 
in the suboptimal debulking ovarian cancer. This study 
also revealed even in the unresponsive IV 
chemotherapy, IP route would be a good option. 
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